Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2006 2
2007 3
2008 3
2009 5
2010 2
2011 4
2012 6
2013 7
2014 6
2015 13
2016 10
2017 9
2018 10
2019 11
2020 18
2021 23
2022 29
2023 10
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean takeshige abe (13 results)?
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Yamada S, et al. Among authors: abe t. Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16. Cancer Immunol Immunother. 2023. PMID: 36795123 Free PMC article.
Simulation training in upper tract endourology: myth or reality?
Lovegrove CE, Abe T, Aydin A, Veneziano D, Sarica K, Khan MS, Dasgupta P, Ahmed K. Lovegrove CE, et al. Among authors: abe t. Minerva Urol Nefrol. 2017 Dec;69(6):579-588. doi: 10.23736/S0393-2249.17.02873-9. Epub 2017 Mar 30. Minerva Urol Nefrol. 2017. PMID: 28376609 Free article. Review.
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. Kato T, et al. Among authors: abe t. BMC Cancer. 2022 Dec 9;22(1):1292. doi: 10.1186/s12885-022-10398-6. BMC Cancer. 2022. PMID: 36494792 Free PMC article. Clinical Trial.
GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. Miyata H, et al. Among authors: abe t. Cancer Immunol Immunother. 2022 Apr;71(4):795-806. doi: 10.1007/s00262-021-03025-z. Epub 2021 Aug 18. Cancer Immunol Immunother. 2022. PMID: 34405274 Free PMC article.
154 results